Brown University Researchers Identify MicroRNA-181d as Dual-Action Switch for Glioblastoma Treatment and Immune Memory

Brown University researchers identify miR-181d as a key molecule that blocks tumor repair and trains the immune system to fight aggressive brain cancer.

By: AXL Media

Published: Apr 22, 2026, 4:20 AM EDT

Source: Information for this report was sourced from Brown University Health

Decoding the Biology of Exceptional Responders

In the pursuit of more effective treatments for glioblastoma, the most aggressive primary brain cancer in adults, researchers at Brown University have turned their focus toward a rare subset of "exceptional responders." These are patients who survive significantly longer than the average prognosis, exhibiting a unique sensitivity to standard treatments. By analyzing hundreds of patient tumor samples, the team identified that these individuals possess elevated levels of a microscopic regulator called miR-181d. This molecule appears to be the biological engine behind their extended survival, acting as a "master switch" that dictates how the tumor interacts with both therapy and the host’s immune system.

Incapacitating the Tumor's Genetic Repair Toolkit

Glioblastoma is notoriously resilient because its cells can repair the DNA damage inflicted by radiation and chemotherapy. The Brown research team, including Dr. Jay Hou, an assistant professor of neurosurgery, discovered that miR-181d inhibits a pivotal protein known as RAD51. This protein is essential for homologous recombination, a DNA repair mechanism that allows cancer cells to recover and proliferate after treatment. By naturally lowering RAD51 levels, miR-181d essentially strips the tumor of its defensive toolkit, making the cancer cells far more vulnerable to clinical intervention.

Stimulating Long-Term Anti-Tumor Immune Memory

Beyond its role in sensitizing tumors to radiation, miR-181d provides a critical secondary benefit by activating the body’s immune defense. In pre-clinical trials using immunocompetent models, the introduction of miR-181d prior to radiation therapy did more than just shrink existing tumors; it appeared to induce an "immune memory" response. This rare phenomenon trains the immune system to identify and neutralize glioblastoma cells that may attempt to regrow in the future. Senior author Dr. Clark Chen noted that this ability to keep the immune system engaged long after treatment ends is a hallmark of the most successful cancer outcomes.